The antinociceptive effects of a dual kappa-delta opioid receptor agonist in the mouse formalin test. Issue 2 (April 2020)

• Record Type: Journal Article
• Authors: Ulker, Esad; Toma, Wisam; White, Alyssa; Uprety, Rajendra; Majumdar, Susruta; Damaj, M. Imad
• Is Part Of: Behavioural pharmacology. Volume 31:Issue 2(2020)
• Publication Date: 2020-04
• Subjects: formalin -- mice -- MP1104 -- opioid -- pain; Psychopharmacology -- Periodicals; Nervous System -- drug effects -- Periodicals; Behavior -- drug effects -- Periodicals; 615.78
• DOI: 10.1097/FBP.0000000000000541
• Languages: English
• ISSNs: 0955-8810

Abstract

Abstract : Pain management is a challenging and unmet medical need. Despite their demonstrated efficacy, currently used opioid drugs and nonsteroidal anti-inflammatory drugs are frequently associated with several adverse events. The identification of new and safe analgesics is therefore needed. MP1104, an analogue of 3′−iodobenzoyl naltrexamine, is a potent nonselective full agonist at mu (MOR), kappa (KOR), and delta (DOR) opioid receptors, respectively. It was shown to possess potent antinociceptive effects in acute thermal pain assays without aversion in mice. In this study, we investigated MP1104 in the formalin test, a model of tonic pain. MP1104 (0.05, 0.1, and 1.0 mg/kg) reduced pain-like behaviors in phases I and II of the formalin test in male and female ICR mice. Pretreatment with KOR antagonist (norbinaltorphimine 10 mg/kg) and DOR antagonist (naltrindole 10 mg/kg) abolished the antinociceptive effects of MP1104 in the formalin test. These findings support the development of MP1104 for further testing in other pain models.